ARROWHEAD PHARMACEUTICALS, INC. Marketable Securities, Unrealized Gain (Loss)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Marketable Securities, Unrealized Gain (Loss) of $0 for the 9-month period ending 2023-06-30, per its 10-Q filed 2023-08-07.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-08-07
- ARROWHEAD PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-06-30 was -$1.60M, a 360.91% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2021-06-30 was $614.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month |
|---|---|---|---|
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 | ||
| 2022-06-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | -$5.75M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | -$4.15M 10-Q · filed 2022-05-10 | ||
| 2021-06-30 | $614.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-04 | $1.39M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $773.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |